271 related articles for article (PubMed ID: 33958364)
1. Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis.
Iwahashi K; Kuroki Y; Takano Y; Nagahama M
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33958364
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
4. Pyoderma gangrenosum with primary sclerosing cholangitis-associated colitis successfully treated with concomitant granulocyte and monocyte adsorption apheresis with corticosteroids.
Kawai M; Kawanami C; Fukuda A; Seno H
Clin J Gastroenterol; 2021 Oct; 14(5):1561-1566. PubMed ID: 34101129
[TBL] [Abstract][Full Text] [Related]
5. [Ulcerative colitis complicated by pyoderma gangrenosum and multiple aseptic abscesses].
Kita A; Hashimoto Y; Sato K; Itoi Y; Kasuga K; Tanaka H; Hosaka H; Kuribayashi S; Uraoka T
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(11):1014-1021. PubMed ID: 36351620
[TBL] [Abstract][Full Text] [Related]
6. Refractory pyoderma gangrenosum associated with ulcerative colitis successfully treated with infliximab.
Ueda M; Katoh M; Tanizaki H; Tanioka M; Matsumura Y; Miyachi Y
Dermatol Online J; 2012 Jan; 18(1):12. PubMed ID: 22301049
[TBL] [Abstract][Full Text] [Related]
7. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery.
Andrisani G; Guidi L; Papa A; Potenza AE; Cervelli D; Armuzzi A
J Crohns Colitis; 2013 Jun; 7(5):421-6. PubMed ID: 22889645
[TBL] [Abstract][Full Text] [Related]
8. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis.
Shibuya T; Haga K; Saeki M; Haraikawa M; Tsuchihashi H; Okahara K; Nomura O; Fukushima H; Murakami T; Ishikawa D; Ikeda S; Nagahara A
J Clin Apher; 2020 Sep; 35(5):488-492. PubMed ID: 32767842
[TBL] [Abstract][Full Text] [Related]
9. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine.
Futami H; Kodaira M; Furuta T; Hanai H; Kaneko E
J Gastroenterol; 1998 Jun; 33(3):408-11. PubMed ID: 9658322
[TBL] [Abstract][Full Text] [Related]
10. Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis.
Koskinas J; Raptis I; Manika Z; Hadziyannis S
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1421-4. PubMed ID: 10654805
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
Baglieri F; Scuderi G
Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
[TBL] [Abstract][Full Text] [Related]
12. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature.
Ohmura SI; Homma Y; Hanai S; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Jan; 7(1):9-13. PubMed ID: 35285489
[TBL] [Abstract][Full Text] [Related]
13. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
López San Román A; Bermejo F; Aldanondo I; Carrera E; Boixeda D; Muñoz Zato E
Rev Esp Enferm Dig; 2004 Jun; 96(6):420-2; 422-4. PubMed ID: 15230672
[TBL] [Abstract][Full Text] [Related]
14. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
15. Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions.
Sagami S; Ueno Y; Tanaka S; Nagai K; Hayashi R; Chayama K
Intern Med; 2015; 54(17):2167-72. PubMed ID: 26328641
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNFα Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease.
Nedelkopoulou N; Vadamalayan B; Vergani D; Mieli-Vergani G
J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):100-105. PubMed ID: 28953529
[TBL] [Abstract][Full Text] [Related]
18. Pyoderma gangrenosum associated with sclerosing cholangitis, type 1 diabetes mellitus and ulcerative colitis.
Goreti Catorze M; Pereira F; Fonseca F; Morbey A; Assis Pacheco F
J Eur Acad Dermatol Venereol; 2001 May; 15(3):257-9. PubMed ID: 11683294
[TBL] [Abstract][Full Text] [Related]
19. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
[TBL] [Abstract][Full Text] [Related]
20. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
